Physician profile
Janice Daniel
NPI 1932701117
$2,676.55
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $891 · 2022: $651 · 2023: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $449.26 | 2021-2023 | Farxiga |
| Abbvie INC. | $354.31 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.71 | 2021-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $271.02 | 2021-2022 | |
| Novo Nordisk INC | $249.10 | 2022-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $170.01 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $137.74 | 2021-2022 | |
| Amgen INC. | $131.19 | 2021-2023 | Repatha, Otezla |
| Lilly USA, LLC | $105.22 | 2023 | Mounjaro |
| Exact Sciences Corporation | $97.43 | 2023 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $66.43 | 2022-2023 | |
| Eisai INC. | $48.40 | 2021 | |
| Astellas Pharma US INC | $47.91 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.66 | 2023 | |
| Scilex Pharmaceuticals INC. | $41.94 | 2021-2023 | Ztlido |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $41.23 | 2021 | |
| Tactile Systems Technology INC | $27.43 | 2021 | |
| Idorsia Pharmaceuticals US INC | $24.81 | 2022 | |
| Arbor Pharmaceuticals, INC. | $22.81 | 2021 | |
| Amarin Pharma, INC. | $21.42 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.92 | 2023 | Qelbree |
| Sanofi-Aventis U.S. LLC | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.